Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2710-2722

  Varsano, Tal ^a   Lau, Eric ^a   Feng, Yongmei ^a   Garrido, Marine ^a   Milan, Loribelle ^a   Heynen Genel, Susanne ^a   Hassig, Christian A ^a   Ronai, Ze'ev A ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ACTIVATING TRANSCRIPTION FACTOR 2; ANTINEOPLASTIC AGENT; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; N [(4 METHOXY 1 NAPHTHYL)METHYL] 2 (4 METHOXYPHENYL)ETHANIME; N [2 (1 ADAMANTYL)ETHYL] 4 [(DIMETHYLAMINO)SULFONYL]BENZAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; SBI 0087702; SBI 0089410; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; ATF2 PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; MOLECULAR LIBRARY; NAPHTHALENE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; SBI-0087702; SBI-0089410; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; 3T3 CELL LINE; ANIMAL; CELL CYCLE; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DNA MICROARRAY; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOBLOTTING; METABOLISM; MITOCHONDRION; MOLECULAR LIBRARY; MOUSE; PATHOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MELANOMA; MICE; MICROSCOPY, CONFOCAL; MITOCHONDRIA; MOLECULAR STRUCTURE; NAPHTHALENES; NIH 3T3 CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENETHYLAMINES; PROTEIN KINASE C-EPSILON; PROTEIN TRANSPORT; SMALL MOLECULE LIBRARIES; SULFONAMIDES;

EID: 84878041279     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2689     Document Type: Article

References (22)

1. Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2011;223:241-50.
2. Shepherd C, Puzanov I, Sosman JA. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep 2010;12:146-52.
3. Smalley KS. Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol 2010;130:28-37.
4. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
5. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467:596-9.
6. Lopez-Bergami P, Lau E, Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer 2010;10:65-76.
7. Bhoumik A, Lopez-Bergami P, Ronai Z. ATF2 on the double-activating transcription factor and DNA damage response protein. Pigment Cell Res 2007;20:498-506.
8. Lau E, Ronai ZA. ATF2-at the crossroad of nuclear and cytosolic functions. J Cell Sci 2012;125:2815-24.
9. Shah M, Bhoumik A, Goel V, Dewing A, Breitwieser W, Kluger H, et al. A role for ATF2 in regulating MITF and melanoma development. PLoS Genet 2010;6:e1001258.
10. Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S, et al. Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A 2008;105:1674-9.
11. Maekawa T, Shinagawa T, Sano Y, Sakuma T, Nomura S, Nagasaki K, et al. Reduced levels of ATF-2 predispose mice to mammary tumors. Mol Cell Biol 2007;27:1730-44.
12. Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63: 8103-7.
13. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 2009;27: 5772-80.
14. Lau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL, et al. PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012;148:543-55.
15. Bhoumik A, Jones N, Ronai Z. Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A 2004;101:4222-7.
16. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001;7:331-42.
17. Bhoumik A, Huang TG, Ivanov V, Gangi L, Qiao RF, Woo SL, et al. An ATF2-derived peptide sensitizesmelanomas to apoptosis and inhibits their growth and metastasis. J Clin Invest 2002;110:643-50.
18. Bhoumik A, Gangi L, Ronai Z. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004;64:8222-30.
19. Halaban R, Alfano FD. Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 1984;20:447-50.
20. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
21. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 Opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012;149:1536-48.
22. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68: 3077-80.